2. Triple negative breast cancer: hormone receptor negative (ER < 10% and PgR < 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory. Both the diagnostic core-biopsy performed prior to neoadjuvant chemotherapy and the residual disease assessed on the surgical specimen should show a triple negative receptor status, as defined by the protocol. Patients with discordant triple negative status will not be eligible.